


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68		A2	(11) International Publication Number: WO 99/39001	
			(43) International Publication Date: 5 August 1999 (05.08.99)	
(21) International Application Number: PCT/EP99/00918			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 2 February 1999 (02.02.99)				
(30) Priority Data: 98300741.0 2 February 1998 (02.02.98) EP				
(71) Applicant (for all designated States except US): AMERSHAM PHARMACIA BIOTECH AB [SE/SE]; Bjorkgatan 30, S-751 84 Uppsala (SE).				
(71)(72) Applicant and Inventor: ULFENDAHL, Per, Johan [SE/SE]; Rapphovsvagen 10B, S-756 53 Uppsala (SE).				
(74) Agents: PENNANT, Pyers et al.; 1 Serjeants' Inn, Fleet Street, London EC4Y 1LL (GB).				
		Published	Without international search report and to be republished upon receipt of that report.	

(54) Title: NUCLEIC ACID ANALYSIS METHOD

(57) Abstract

A nucleic acid analysis method comprises: using a primer to amplify the nucleic acid; providing an array of probes, each probe comprising a sequence identical to the primer and an adjacent sequence; applying fragments of the amplifier nucleic acid under hybridisation conditions to the array; effecting enzymatic chain extension of any probe where the adjacent sequence matches that of a hybridised fragment of the amplified nucleic acid; and observing the location of probes of the array while chain extension has taken place.



BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NUCLEIC ACID ANALYSIS METHOD

5 Background

This invention concerns the characterisation, classification, identification and typing of different DNA containing organisms such as plants, animals, bacteria and their viruses.

The science of detecting genomic polymorphisms is quickly 10 evolving, and several techniques have been developed to compare the genomes of different organisms. These techniques utilise the whole genome or segments thereof for comparison purposes and are often referred to as DNA fingerprinting techniques. The main application fields for these techniques are gene mapping, detection of bacterial strain 15 diversity, population analysis, epidemiology, gene expression and the demonstration of phylogenetic and taxonomic relationships.

In the application areas of bacterial identification and typing, pulsed-field gel electrophoresis, random amplified polymorphic DNA (RAPD) and DNA sequencing of different genes are frequently discussed 20 as methods of the future, compared to traditional methods based on biochemical and growth properties. The drawback with all these and other suggested DNA fingerprinting methods is the use of electrophoresis. This is because electrophoresis is a laborious separation technology and the time from start to finish is long, ranging from 30 minutes up to more than 20 25 hours for pulsed-field gel electrophoresis, followed by both detection of the DNA and analysis of the results.

Since ribosomes are present in all living organisms, and the ribosomes contain three kinds of rRNA (in bacteria 5 S, 16 S, and 23 S), DNA sequencing of the corresponding genes is frequently used for 30 characterisation, identification and taxonomy relations of bacteria, fungi and other organisms. The most widely used of the ribosomal genes is

16 S rDNA. The DNA sequences of these genes contain well-defined segments of different evolutionary variability regions, which in the 16 S rRNA molecule are referred to as universal, semi-conserved and variable regions. Oligonucleotide primers complementary to universal 5 regions can be used for amplification of ribosomal RNA from any organism or bacteria, the generated ribosomal fragment being then sequenced. In a computer search against a database with all known ribosomal sequences the species can be assigned.

Random amplified polymorphic DNA (RAPD) is a process for 10 detecting polymorphisms on the basis of nucleotide differences and is covered by US patent 5,126,239 of Livak *et al*, 1992. RAPD analysis is one of the most sensitive, reproducible and efficient methods currently available in the research field for distinguishing different strains and isolates of a species. RAPD analysis is a technique that uses a single 15 short oligonucleotide primer of arbitrary sequence in a low stringency amplification reaction (Welsh J and McClelland M, 1990, Nucleic Acids Research, 18 (24), 7213-7218; Williams J G *et al* (1990) Nucleic Acids Research, 18, 6531-6535). The generated DNA fragments are subsequently analysed by gel electrophoresis. Analysis can either be done 20 automatically on line with an automated DNA sequencer or on any electrophoresis gel and stained with ethidium bromide or silver.

In arrayed primer extension techniques (APEX), primers 25 which have hybridised with a template, having a free 3'-end and having a free hydroxyl group, can be extended with free dNTPs and a DNA polymerase. If ddNTPs or other chain terminators are added to the mixture the elongation will terminate at that point. A similar method to this was developed for mutation detection (WO 91/13075). The authors used a PCR template bound to wells of a microtitre plate, and the primers were added for extension after binding to the template.

30 Further development of this method was carried out where consecutive primers overlapping each other by one base were bound to a

support in the form of an array (also called a DNA chip). These were bound to the surface by the 5'-end, so that the 3'-end was free for elongation after addition of template, ddNTP and a polymerase. The chain terminating molecules were labelled, with any type of chromophore, 5 fluorophore, isotope or antibody reactive reagent. This technique is described in WO 95/00669.

The Invention

The present invention combines features of random amplified 10 polymorphic DNA (RAPD) and of arrayed primer extension (APEX), techniques, so as to avoid the difficulty and delay of gel electrophoresis.

In one aspect, the invention provides a nucleic acid analysis method which comprises:-

- a) using a primer to amplify the nucleic acid,
- 15 b) providing an array of probes in which each probe comprises a primer sequence that is identical to (or complementary to) the sequence of the primer, and an adjacent sequence which is different in each probe of the array,
- c) applying the amplified nucleic acid from a) under hybridisation 20 conditions to the array of b),
- d) effecting enzymatic chain extension of any probe where the adjacent sequence matches that of the hybridised amplified nucleic acid, and
- 25 e) observing the location of probes of the array where chain extension has taken place in d).

The nucleic acid to be analysed may be genomic DNA or RNA e.g. mRNA of an organism such as a plant, animal, bacteria or virus. The method is expected to be useful for applications where RAPD analysis is currently used, including gene mapping, detection of strain diversity, 30 population analysis, epidemiology, the demonstration of phylogenetic and taxonomic relationships, and gene expression studies.

In step a) the nucleic acid to be analysed is amplified using a single primer (or possibly several primers) in a low stringency amplification reaction e.g. by PCR. This primer is a chain of units capable of hybridising in a substantially sequence-specific manner to a suitable chain of the

5 nucleic acid to be analysed; to form a hybrid in which the primer chain is capable of enzymatic chain extension. The primer is composed of units which are either nucleotides or nucleotide analogues.

Generally speaking, a nucleotide analogue is a compound which is capable of being incorporated in a chain of nucleotide residues; 10 and which is capable of hybridising in a more or less base-specific manner with a base of a complementary nucleic acid chain; and which may be a substrate for chain-extending enzymes. A nucleotide analogue may be a nucleotide modified: in the base, e.g. so as to affect base-pairing properties; and/or in the sugar or backbone moiety, e.g. as in ddNTPs and 15 in the amide linked backbones of PNA; and/or in the phosphate moiety.

For the primers for this invention, peptide nucleic acids are of interest. Preferably however the primer is an oligonucleotide. The primer preferably has from 7 – 40 residues. Usually a short primer with 8 – 10 residues is used, but primers with up to 20 or 40 residues are also possible. 20 After amplification, all amplimers will have the same sequence at both ends, the length of that sequence depending on the primer.

In many techniques where amplification is involved, there is a need for standardised reagent supply. For this purpose it may be convenient to use Ready-To-Go™ (RTG) RAPD beads marketed by 25 Amersham Pharmacia Biotech which provide the reagents for the reactions. The RTG RAPD beads contain thermostable polymerases, dNTPs, BSA and buffer for a 25 µl reaction.

Preferably the amplified nucleic acid is broken into fragments. Fragmentation is preferred because only small fragments may have access 30 to a probe bound on a solid support. In the examples below, two different approaches have been used, restriction enzymes and the enzyme uracil-

DNA-glycosylase (UDGase). To use UDGase, dUTP must be added to the amplification mix. UDGase activity is blocked by a UDGase inhibitor.

Other enzymatic, chemical and physical methods of breaking the amplified nucleic acid are known and may be used.

5 An important feature of this invention is the use of an array of immobilised probes. These are herein called probes, although they also act as primers for chain extension. Each immobilised probe comprises a primer sequence that is identical to (or complementary to) the sequence of the primer used in a). Each probe also comprises an adjacent sequence, 10 generally of 1 – 8 nucleotide (or nucleotide analogue) residues. The adjacent sequence of each probe of the array is different from that of every other probe of the array. Preferably the array consists of a complete set of probes having adjacent sequences of a particular length, that is to say: 15 four probes where each adjacent sequence is 1 nucleotide residue; or 16 probes where each adjacent sequence is 2 nucleotide residues; or 64 probes where each adjacent sequence is 3 nucleotide residues; or 4^n probes where each adjacent sequence is n nucleotide residues.

20 Preferably the adjacent sequence is positioned at the 3'-end of the primer sequence of the probe. Preferably the probe is tethered to a support through the 5'-terminal residue of the primer sequence, either 25 covalently or by means of strong binding agents such as the streptavidin-biotin system.

25 In step c), the fragments of the amplified nucleic acid from a) are applied under hybridisation conditions to the array. Because all probes of the array include a primer sequence complementary to the primer-derived sequence of the amplified nucleic acid, hybridisation takes place at 30 every probe location of the array.

30 In step d) template-directed chain extension of probes of the array is effected. Preferably this chain extension is performed using a polymerase enzyme together with a supply of nucleotides or nucleotide analogues. Under these circumstances, chain extension only takes place

where the nucleotide residues at the 3'-end of the probe accurately match those of the hybridised nucleic acid fragment.

For this purpose a nucleotide analogue may have a base analogue that is degenerate, by having the ability to base pair with two or 5 three of the natural bases, or universal, by forming base pairs with each of the natural bases without discrimination. Also, chain-terminating ddNTPs may be used as nucleotide analogues, and are preferred.

Nucleotides or nucleotide analogues for addition during the chain extension step may be labelled for ease of detection. The nature of 10 the label is not material to the invention. Examples are radioisotopes, fluorescent moieties, haptens, and components of chromogenic or chemiluminescent enzyme systems. Preferably the four ddNTPs are used, each labelled with a different fluorescent or other label, so that the four different signals can be read simultaneously.

15 Step e) of the method involves observing the location of probes of the array when chain extension has taken place in d). This observation can be made by standard means using the one or more labels added during chain extension. The result is a pattern which is characteristic of the nucleic acid being analysed.

20 In another aspect the invention provides a nucleic acid analysis kit comprising:

- i) a primer for amplifying a nucleic acid,
- ii) an array of probes in which each probe comprises a primer sequence that is identical to (or complementary to) the sequence of the primer, and an adjacent sequence which is different in each probe of the array,
- 25 iii) and reagents for effecting enzymatic chain extension of nucleic acid hybrids.



Description of the ordered arrangement of an array of oligonucleotide probes.

An oligonucleotide primer typically has 7 to 40 nucleotides; for example with 10 nucleotides: 5'-NNNNNNNNNN-3'-OH. Oligonucleotide probes generally comprise oligonucleotide primers and an additional 1-8 bases; for example with 2 additional bases a total of 16 (4^2) probes are needed:

	NNNNNNNNNNAA	NNNNNNNNNNCA
	NNNNNNNNNNAC	NNNNNNNNNNCC
10	NNNNNNNNNNAG	NNNNNNNNNNCG
	NNNNNNNNNNAT	NNNNNNNNNNCT
	NNNNNNNNNNNGA	NNNNNNNNNNNTA
	NNNNNNNNNNNGC	NNNNNNNNNNNTC
15	NNNNNNNNNNNGG	NNNNNNNNNNNTG
	NNNNNNNNNNNGT	NNNNNNNNNNNTT

for 3 additional bases $4^3 = 64$ probes are needed, etc. up to $4^8 \approx 65.000$.

After hybridisation and extension of an array of 64 probes,
20 two different patterns can look like this;



Reference is directed to the accompanying drawings, in
which:-

25 Figure 1 illustrates the principle of the invention. A template

- 8 -

DNA fragment has a 10-mer oligonucleotide primer at its 3' end. An oligonucleotide probe has been immobilised on a surface of a support through a T_{12} anchor joined at the 5'-end of (the complement of) the 10-mer oligonucleotide primer sequence. The oligonucleotide probe carries at its 5 3'-end a random 3-mer extension, in this case TCA.

The template DNA fragment has hybridised to the oligonucleotide probe. By chance the sequence of the template DNA (AGT) complements the 3-mer extension at the 3'-end of the oligonucleotide probe. As a result, template-directed chain extension of the 10 oligonucleotide probe has taken place, and a total of seven nucleotides (N) or labelled nucleotide analogues (*) have been added to its 3'-end.

Figure 2 is a corresponding diagram showing an array of oligonucleotide probes, together with three fragments of template DNA where hybridisation and chain extension have taken place.

15 Figure 3 shows bacterial genotyping data obtained in Example 1 on two different strains of *E. coli* using three different primers.

Figure 4 shows TIRF data obtained on six different strains of *Listeria* in Example 3. For each strain, the upper four panels show images obtained with four different labelled ddNTPs; and the lower panels show 20 the data expressed graphically (capital letters are strong signals, lower case letters are weak signals).

25 Figure 5 comprises four dendograms and contains a comparison between strong and weak assigned spots from the images. Primer 2 was compared with primer 6 amplified *Listeria* DNA in combination with two polymerase enzymes.

In the examples below, the acronym RAPX is used to denote the method of the present invention comprising a combination of the random amplified polymorphic DNA (RAPD) and arrayed primer extension (APEX) techniques.

EXAMPLES

The first example shows the invention method performed in microtitre plates (MTP) with both fluorescein labelled dCTP and anti-fluorescein antibodies and detected by using para-nitrophenyl phosphate (pNpp). Two different bacterial DNA were used in order to show that different patterns could be generated.

The second example shows the method performed on a microscope slide with one of the bacterial DNA as template.

Fragmentation is an important step because only small 10 fragments will have access to the bound primer on the solid support. For this step two different approaches were used, restriction enzyme cleavage and using the enzyme Uracil-DNA-glycosylase (UDGase). To use UDGase, dUTP must be added to the amplification mix. UDGase activity is blocked by a UDGase inhibitor.

15 The whole procedure consists of the following steps:

RAPD amplification

Digestion/Fragmentation

Purification and quantification

Array setup on chip or MTP

20 Hybridisation and chain extension

Detection of reacted products

Example 1

Genomic DNA was purified from *E.coli* strains according to 25 standard protocols. Test DNA from Pharmacia Biotech RTG™ RAPD kit was used.

RAPD amplification:

Each DNA was amplified generally according to the 30 manufacturer's protocol and with the RTG RAPD beads. One reaction contained 25 pmol primer, 10 ng bacterial DNA and water to 25 µl.

- 10 -

Primers: Primer 2: GGTGCAGGAA
 Primer 6: CCCGTCAGCA
 Primer 1283: GCGATCCCCA

Escherichia coli strains: BL21 and C1a

5 When large quantities of RAPD templates are needed several batches of the same sample were amplified, following the prescribed RAPD protocol.

	Number of Cycles	Temp	Time
10	1 cycle	50°C	8 minutes
	1 cycle	95°C	3 minutes
	45 cycles	95°C	1 minute
	36°C	1 minute	
	72°C	2 minutes	
15	1 cycle	35°C	30 minutes

Five microlitre of material from each tube were tested on a polyacrylamide gel.

20 Digestion

The generated RAPD products were fragmented according to two different methods, restriction enzyme cleavage or using the enzyme UDGase.

25 Cleavage with Restriction Enzymes

The RAPD product (DNA) was cleaved with Alu1 and Hha1.

Ingredient	1 Tube
Sterile water	240 µl
Restriction Buffer	40 µl
30 Alu1 Enzyme (3.5)	25 µl (75 units)

- 11 -

RAPD product (DNA)	95 μ l
TOTAL	400 μ l

Incubate tubes for 1 hour in a 37°C oven.

5 Place 100 μ l of the following master mix in each tube:

Ingredient	1 Tube
Sterile water	15 μ l
Restriction Buffer	60 μ l
10 Hha1 Enzyme (3.6)	25 μ l (75 units)
TOTAL	400 μ l

Incubate for 2 hours in a 37°C oven.

After cleavage 5 μ l was tested on a polyacrylamide gel.

15

Cleavage with UDGase

Bacterial DNA was amplified with an addition of 80 mM dUTP before treatment with UDGase and UDGase inhibitor (UDI).

20 One RAPD reaction contained 25 pmol primer, 10 ng bacterial DNA, 80 mM dUTP (Pharmacia Biotech), water to 25 μ l and one RTG RAPD bead, with the same amplification conditions as above.

UDGase treatment, set up:

25 μ l RAPD DNA
25 6.25 μ l UDGase (1U/ μ l New England Biolabs)
6.25 μ l 10x UDGase mix
25 μ l water
Incubate at 37°C for 24 min.
Add 6.25 μ l UDI
30 Incubate at, at least 75°C, for 10 minutes and test on polyacrylamide gel.

- 12 -

Purification and quantification

Cleaved RAPD products were concentrated with a Centricon-10 Concentrator. The concentrated DNA was then filtered through an Amicon EZ filter to remove excess of primers, free nucleotides and enzymes.

Finally, the DNA concentration was measured using Optical Density at 260nm and 280nm using spectrophotometer and calculate the volume to get 2.5 µg DNA for the hybridisation and extension reactions.

10 Preparation of array plates

Three sets of 64 oligonucleotides with primer sequences from primers 2, 6 and 1283 extended with all possible combinations of three additional nucleotides (nt), giving them a total length of 13 nt, were bound to microtitre plate wells.

15

Reactions in wells

RAPD DNA template (2.5 µg) was added to each well and heated to boiling temperature for 3 minutes.

	<u>Order</u>	<u>Component</u>	<u>Volume- 1 well</u>
20	1	water	79.2 µl
	2	5x TSP buffer	20 µl
	3	Deoxy Mix	0.1 µl
	4	Fl-dCTP (.5 mmol)	0.2 µl
	5	Tba Polymerase	0.5 µl
25		Total	100 µl

Tba Polymerase is a DNA polymerase from the bacterium *Thermococcus barroissi*.

After adding the reaction mix, incubate at 72°C for 45 minutes 30 in a large oven.

- 13 -

5X Thermostable Polymerase Reaction Buffer (TSP)

<u>Component</u>	<u>Volume</u>	<u>[Final]</u>
1M Tris-HCl, pH 9.5	10 μ l	100 mM
1M MgSO ₄	5 μ l	50mM
10% Triton X-100	25 μ l	2.5%
Milli Q TM water	60 μ l	
		100 μ l

10 Mix. Sterile filter. Store at room temperature.

15 dNTP (Deoxy) Mix (dA, dG, & dT)

<u>Component</u>	<u>Volume</u>	<u>[Final]</u>
100 mM dATP	5 μ l	1 mM
100 mM dGTP	5 μ l	1 mM
100 mM dTTP	5 μ l	1 mM
Milli Q TM water	485 μ l	
		500 μ l

20 Store at -20°C.

Detection of reaction products

25 In order to enhance the signal, anti-fluorescein antibodies labelled with alkaline phosphatase were used. Before detection of the reaction, each well was blocked with a buffer containing bovine serum albumin. One hundred microlitre of anti-fluorescein antibody solution was pipetted in to each well and incubated 60 minutes at room temperature.

30 The microtitre plate was washed several times before para-nitrophenyl phosphate reagent was added and a yellow colour was developed at room temperature.

35 The yellow signal output read from each well is a quantitative measure on the amount of the RAPD fragment for that particular RAPD-extended probe. All data from the reader (Spectra Max 3000) was used for

generation of a graph for each organism, Figure 3.

This is a set of overlaid duplicate optical density readings. Signals have been determined by high values that have consistently shown up through four experiments that have compared these two strains of bacteria.

In the centre is a bar code that represents signals for the two strains.

Example 2

This experiment was performed to show that the method of the invention also works when the array of oligonucleotide probes is on a glass surface. For this purpose, silanised glass slides were procured and three sets of the three oligonucleotide probe families of Example 1 (3 x 64 = 192 probes) were synthesised to have amino-linked 5' -modified ends.

These oligonucleotide probes were spotted on to the silanised surface of the glass slide, the experiment being performed in triplicate. Border controls (self-extending oligonucleotides capable of A, G, T or C addition) were spotted in a pattern that surrounded each of the four spotted grids.

Nucleic acid template material was prepared, as described in Example 1, starting from genomic DNA of the *E.coli* strain BL21. Template material was validated by running samples on polyacrylamide gel and staining with ethidium bromide. It was found that the material digested with the mixture of frequent cutting enzymes (Alu1 and Hha1) seem to average about 250 bp in size (50 – 500 bp range).

Hybridisation and extension reactions were performed generally as described in Example 1. The extension reaction mix was:

13.5 μ l RAPD DNA fragments (2 pmol)
1 μ l 17.5x Thermosequenase DNA polymerase buffer
1 μ l unlabelled dNTPs (50 mM)
1 μ l Cy5-ddCTP (50 mM)
1 μ l Thermosequenase DNA polymerase (5U/ μ l)

Incubate at 65°C during 20 minutes. The Cy5-ddCTP was a sulphonated cyanine dye dideoxy nucleotide marketed by Dupont. Control reactions were first performed in order to ensure the presence of correctly spotted oligonucleotides and validate a successful enzyme reaction. In the 5 presence of polymerase enzyme without any template, only the border controls appeared. The addition of three different oligonucleotides that would specifically hybridise to one of each of the primer families, resulted in the detection of the appropriate spots in the array. These control experiments demonstrated the ability to perform specific reactions on the 10 microscope slide surface.

Template nucleic acid material (prepared as described in Example 1) that represents sequence information of the bacterial genome BL21 was then applied to the oligonucleotide probe array. Using a total internal reflection detection system, a specific pattern of signals was seen 15 for template material from the BL21 source.

Example 3

Amplification:

- Bacterial DNA: *E. coli* BL21 and *E. coli* C1a strains are from 20 the Amersham Pharmacia Biotech RTG RAPD kit. Six *Listeria monocytogenes* strains are *Listeria monocytogenes*; serotype 1, serotype 2, serotype 4a, serotype 4b, ATCC 15313 and ATCC 35152.
- Primers: Primer 2, 6 are from the Amersham Pharmacia Biotech RTG RAPD kit and primer 1283 is from Berg *et al.*
- Amplification reagents: RAPD RTG beads from the 25 Amersham Pharmacia Biotech RTG RAPD kit.
- All samples were spiked with one microliter 2.5 mM dUTP

- 16 -

Enzymes for fragmentation of RAPD products:

- Shrimp alkaline phosphatase (SAP) 1 U/µl APB.
- Uracil-DNA-glycosylase, (if from PE UDG = UNG) 1 U/µl NE

Biolabs

5 SAP will degrade (dephosphorylate) all free dNTPs and UDG will remove all dU from the DNA and after heating the strands will be broken at these points. This step is applicable to any DNA fragment.

Primers for spotting:

10 All 192 primers were 25-mers with an amino-activated 5'-end.

The general sequence for the primers is

5'-NH₄-TTT TTT TTT TTT - P - N₁N₂N₃ - 3', where P is the primer sequence from Primer 2, Primer 6 or Primer 1283; and N₁₋₃ is A, C, G or T. For the arrangements of the primers see below.

15 In Primer 2 set up P = GTTTC GCTCC, Primer 6 set up

P = CCCGT CAGCA, and in Primer 1283 set up P = GCGAT CCCCA.

N									N
T ₁₂ P-									
TGA	TA	AA	GA	GA	CA	AA	AG	AA	
T ₁₂ P-									
TGC	TA	CG	GC	GC	CA	AC	AG	AC	
T ₁₂ P-									
TGG	TA	GG	GA	CG	CA	AG	AA	AG	
T ₁₂ P-									
TGT	TA	GG	GAT	CGT	CAT	AGT	AAT		
T ₁₂ P-									
TTA	TCA	GTA	GCA	CTA	CCA	ATA	ACA		
T ₁₂ P-									
TTC	TCC	GTC	GCC	CTC	CCC	ATC	ACC		
T ₁₂ P-									
TTG	TCG	GTG	GCG	CTG	CCG	ATG	ACG		
T ₁₂ P-									
TTT	TCT	GTT	GCT	CTT	CCT	ATT	ACT		
N									N
			T	G	C	A			
	Cy2	Cy3	Cy5						

A is a self extended primer that only extends with A;
 C is a self extended primer that only extends with C;
 G is a self extended primer that only extends with G;
 T is a self extended primer that only extends with T;
 N is a mix of A, C, G, and T, self extending primers.

Cy2, Cy3 and Cy5 are pre-labelled primers with respectively dye. (Can also be self extended in some cases.)

Extension reagents for the APEX reaction

• Dyes:

Cy2 - ddCTP (equal to fluorescein)	50 μ M
Cy3 - ddGTP	50 μ M
5 Cy3 - ddATP	50 μ M
Cy5 - ddUTP (often written as T in many of the reactions and results)	50 μ M

Dye mixes may vary from time to time, use normal stocks of 50 μ M.

10 • 10x ThermoSequenase DNA polymerase buffer (TS): 260 mM Tris-HCl pH 9.5; 65 mM MgCl₂, this buffer does not have high influence on the APEX reaction.

15 • ThermoSequenase DNA polymerase (from Amersham Pharmacia Biotech (APB)) 4 U/ μ l. If needed dilute with T.S. dilution buffer (=10 mM Tris-HCl pH 8.0; 1 mM β -mercaptoethanol, 0.5% Tween-20 (v/v), 0.5% Nonidet P-40 (v/v)).

20 • KlenTaq X DNA polymerase (WO 92/06188 with the same mutation for improved ddNTP incorporation as in Thermosequenase DNA polymerase) ~5 U/ μ l.

MethodsPreparation of glass slides before spotting of primer:

25 1. Arrange 25-30 cover slips (24 x 60 mm) in a stainless staining tray.

2. Immerse the tray in glass staining dish with acetone to fully immerse slides.

3. Place the glass staining dish in sonicator for 10 minutes.

4. Remove the tray from acetone bath, shake off excess of acetone and rinse several times (at least twice) in MilliQ water.
5. Immerse tray in 100 mM NaOH and sonicate for 10 minutes (a few more minutes, no problem).
- 5 6. Remove the tray and shake off the excess of NaOH and rinse several times (at least twice) in MilliQ water.
7. Immerse tray in silane solution and sonicate for 2 minutes.
8. Wash slides by immersion in 100 % EtOH once. (Silane and silane contaminated EtOH in special container for silane discharge.)
- 10 9. Dry the tray with the slides in nitrogen with a high velocity (without breaking the slides).
10. Cure the slides in a vacuum oven at 100 °C over night or until they are used for spotting (at least 20 minutes vacuum is not needed).

15 Spotting of oligos:

All spotting was done with a lab made spotter with 96 parallel capacity. Each slide was spotted with three replicas of the primers.

After spotting the slides were allowed to air dry for 5 to 15 minutes, when dried and marked. They were stored at room temperature, 20 in a dry place, in the trays until used. Chips can be used for a few weeks, probably longer. Arrangements of oligos and sequences see above.

RAPD amplification

The RAPD amplification were done according to the 25 Ready-To-Go RAPD instruction. After 45 cycles (96 °C, 1 min.; 36 °C, 1 min.; 72 °C, 2 min.), one microliter of the products was tested on a 4-20% premade PAGE, before the fragmentation step.

- 19 -

Fragmentation of RAPD (DNA fragment) products:

Before RAPX (APEX) can be done all DNA fragments must be fragmented so all new fragments can get access to the primer on the chip.

5

Set up:

20 µl DNA from RAPD reaction

0.5 µl SAP (Shrimp alkaline phosphatase) 1 U/µl

0.5 µl UDG (Uracil-DNA-glycosylase, if from PE UDG = UNG)

10 1 U/µl NE Biolabs

Total: 21 µl

Incubate 37 °C for 1 hour.

Inactivate enzymes at 100 °C for 10 minutes.

The samples can now be frozen and stored until they are used.

15

Extension method for the APEX reaction

Slide treatment:

Start with washing the slides in hot water (90 - 98 °C, not boiling) for 2 x 5 minutes in a 50 ml Falcon tube. When the slides are

20 ready, remove them from the tube with a forceps and place them on a dry heater block at 48°C. The slide (DNA chip) is now ready for adding the reactions.

RAPX reactions set up:

25 1. 4 - 5 µl DNA from RAPD reaction (or from PCR reaction if an APEX slide has been used). Note that the DNA must be fragmented before this step.

2. 3 µl 10x TS buffer (the rest of the buffer comes from PCR and UDG cleavage)

- 20 -

3. Water to 38 μ l for dry-down method or 18 μ l for cover slip method.
4. Heat denature at 100°C for 7 - 10 minutes, target 8 minutes, not longer.
5. 5. Spin the tube quickly and add quickly
6. 1 μ l ThermoSequenase DNA polymerase (4U)
7. 1 μ l Dye-mix (up to three dyes at the same time and quick spin and load on the slide).

These three last steps must be done under 1 minute, in order 10 not to let DNA fragments renature. If cover slips are used, each reaction needs 20 μ l, but the dry-down method is preferred, where all 40 μ l of the reaction is physically spread out over the primer array with help of the tip of a pipette tip.

8. Incubate at 48 °C for 20 minutes with cover slip.
15. Alternatively, the so called dry-down method can be used were the spread mix is allowed to dry down until no trace of solution is seen. This takes about 8 minutes. The signals with cover slips were better and with lower background.
9. Wash with hot water for 2-5 minutes, 2 times.
20. 10. Ready to read on TIRF instrument.

Detection

The detection system is a total internal reflection fluorescence (TIRF), where microscopic slides are placed on top of a prism with oil on to 25 link a laser beam in to the glass slide. The system has five different wave lengths from five different lasers to vary between. In this experiment only three were used. To detect Cy2 a laser with 488 nm was used, for Cy3 a 532 nm and for Cy5 a 635 nm laser was used. Image related software was based on Image Pro Plus 3.0.

Results

RAPD amplification

The RAPD amplification was done with RTG RAPD beads in order to use a standardised method for further high reproducibility. The 5 amplified products were analysed on an ethidium bromide stained polyacrylamide gel. The only reference to compare with was the RAPD manual from APB with the different primers and the two *E. coli* stains. The expected bands were seen, and correspond very well. In summary, all DNA were nicely amplified except the *Listeria* DNA with primer 1283, which 10 contained too much broken DNA.

RAPX reaction with *E. coli* DNA

DNA from the two *E. coli* stains BL21 and C1a were amplified and fragmented. The extension reaction is quick to set up and analyse. 15 The extension can be done in two ways, either with or without a cover slip. If a cover slip is used the background is lower and was mainly used in the typing reactions, see below. But, in the first set up, the dry down method with no cover slip was used, which resulted in some circular shaped background.

20 In the set up of primers positive controls were used, in each corner of the matrix a mix of primers were added that always will be extended if the DNA polymerase is active. Below the matrix self extendible primers for the different bases were placed together with Cy-dyed primers for laser control. A self extended primer is a primer that has 25 complementarily to it self or a neighbour, which then can be extended. The neighbour is seen in the cases with the 64 primers and the other control primers are fold back self extenders. The different pre-labelled primers gave expected signals showing that the detector and the imaging system is working. Taken together this show that the DNA polymerase is active and 30 that the system is working perfectly with all positive signals.

After RAPD amplification and fragmentation the two *E. coli* stains BL21 and C1 were analysed on Primer 2 RAPX chips. The two different *E. coli* strains show clearly two different patterns, accordingly these two *E. coli* strains can be separated. Both *E. coli* strains gave four bands after RAPD analysis on PAA. Each band has two ends with the sequence from the primer, the sequence further in is not known. Accordingly, totally 8 spots can light up on a RAPX chip. Three panels with *E. coli* DNA have about 13 stronger signals and the control with no DNA has five signals, this corresponds well with the expected 8 spots. The position of the spots can not be predicted unless each fragment is sequenced or the whole genome of the organism is sequenced.

Typing of six *Listeria* strains with RAPX.

With the good tests with *E. coli* DNA in mind, the next step was to test if different patterns can be generated from several different strains, six strains from *Listeria monocytogenes* were then selected. The chosen strains had been typed with RAPD and analysed on silver stained gels by C. Ko, Hoefer see below, which will make it easier to interpret the results from the RAPX analysis.

Before the typing started the following two tests were done, firstly check of primer chips for self-extendible primers. Secondly, test two different thermostable enzymes, ThermoSequenase DNA polymerase and KlenTaqX DNA polymerase. The comparison of different *Listeria* strains was finally done.

During the work two different thermostable DNA polymerases was used. The majority of reactions were done with ThermoSequenase DNA polymerase, but also KlenTaqX DNA polymerase were used. The new enzyme KlenTaqX DNA polymerase, which is smaller in size than ThermoSequenase DNA polymerase gave stronger signals and lower background, which also made it easier to assign the base on the extended primers. All spots, even the weak ones where informative in the cluster

analysis with elongation with KlenTaqX DNA polymerase, when the clusters from Primer 2 and Primer 6 were compared.

Each sample was analysed two times using two different dye mix systems, since not all terminators are available with dyes with separated spectrum. The two dye mixes were Mix1: Cy2-ddCTP, Cy3-ddGTP, Cy5-ddATP and Mix2: Cy2-ddCTP, Cy3-ddGTP, Cy5-ddUTP. Thus, each sample generated six images, but the assembly of these six images gave a pseudo four dye system, by choosing the best of either "2" or "4", and "3" or "5" to get C and G extendible primers, respectively. The A and T (ddUTP) extendible primers are from Cy5-labelled terminators, "1" and "6".

The next step was to test all *Listeria* strains in the RAPX reaction. It was notable how quick the RAPX analysis is done, even though the reaction was done in duplicate, with two different dye mix combinations. The RAPX reaction takes about 30 minutes, including pipetting, set up and reading the images.

For the analysis of relation between the different strains the best of the triplicate signals on each slide were selected. All signals shown on the image were scored manually and the extended bases were assigned. Figure 4 shows all six *Listeria* strains after analysis with Primer 6, these samples were extended with KlenTaqX DNA polymerase. The same type of data was also generated from Primer 2, but with ThermoSequenase DNA polymerase, data not shown. All assigned bases were stored in a spread sheet software for cluster analysis, which was done in two steps. In the first step all assigned bases were converted to figures and then a similarity table was calculated. Finally a dendrogram was calculated as shown in Figure 5.

When cluster data from a poster made by Chris Ko at Hoefer Pharmacia in San Francisco were compared with the data generated with RAPX, the similarities are seen. Then the dendograms from Primer 6 and 2 data were compared with the dendogram generated by Chris Ko and

were shown to be very similar. The small differences could be explained by the use of different primers in C Ko's experiments.

Conclusions

5 The RAPX method is shown to be a quick and accurate method. It takes approximately 30 minutes to perform the extension, and detection including hands on time and incubations. Different strains can be analysed with the RAPX method and the same cluster/groups can be identified when compared with ordinary gel electrophoresis. The speed and
10 the easiness of the RAPX method guarantee for the future use of this array technology in bacterial typing as well as relationship studies of other organisms. An array format like this method could easily be highly automated.

CLAIMS

1. A nucleic acid analysis method which comprises:-
 - 5 a) using a primer to amplify the nucleic acid,
 - b) providing an array of probes in which each probe comprises a primer sequence that is identical to (or complementary to) the sequence of the primer, and an adjacent sequence which is different in each probe of the array,
- 10 c) applying the amplified nucleic acid from a) under hybridisation conditions to the array of b),
- d) effecting enzymatic chain extension of any probe where the adjacent sequence matches that of the hybridised amplified nucleic acid, and
- 15 e) observing the location of probes of the array where chain extension has taken place in d).

2. The method as claimed in claim 1, wherein the nucleic acid is genomic DNA of an organism.

- 20 3. The method as claimed in claim 1 or claim 2, wherein the primer is an oligonucleotide primer having 7 – 40 nucleotide residues.

- 25 4. The method as claimed in any one of claims 1 to 3, wherein the amplified nucleic acid in a) is broken into fragments.

5. The method of claim 4, wherein a dUTP/uracil-DNA-glycosylase system is used to break the amplified nucleic acid into fragments.

6. The method of any one of claims 1 to 5, wherein the adjacent sequence of each probe of the array contains 1 – 8 nucleotide residues.
7. The method as claimed in any one of claims 1 to 6, wherein 5 different probes of the array occupy different cells on a surface of a support.
8. The method as claimed in any one of claims 1 to 7, wherein each probe is immobilised at its 5'-end.

10

9. The method as claimed in any one of claims 1 to 8, wherein each probe comprises a primer sequence and an adjacent sequence positioned at the 3'-end of the primer sequence.
- 15 10. The method as claimed in any one of claims 1 to 9, wherein chain extension is performed in d) using a polymerase enzyme.
11. The method as claimed in any one of claims 1 to 10, wherein chain extension is performed in d) using labelled nucleotides or labelled 20 nucleotide analogues.
12. The method as claimed in claim 11, wherein labelled dideoxynucleotides are used.

25

13. The method of claim 12 wherein the four dideoxynucleotides, each labelled with a different fluorescent label, are used.
14. The method as claimed in any one of claims 1 to 13, wherein in step e) a pattern of locations is observed and used to compare nucleic 30 acids from one organism with those from another organism.

15. A nucleic acid analysis kit comprising:
 - i) a primer for amplifying a nucleic acid, and
 - ii) an array of probes in which each probe comprises a primer sequence that is identical to (or complementary to) the sequence of the primer, and an adjacent sequence which is different in each probe of the array.
16. The nucleic acid analysis kit of claim 15 comprising also one or more of:
 - iii) reagents for amplifying a nucleic acid,
 - iv) reagents for fragmentation of an amplified nucleic acid,
 - v) and reagents for effecting enzymatic chain extension of nucleic acid hybrids.

Fig.1.




Fig.2.




Fig.3.







Fig.4(i).

Serotype 1



N								
N	T	T	T	T	T	T	T	T
N	T			T	T	T	T	T
N				T	T	T	T	T
N					T	T	T	T
N						T	T	T
N							N	N
N							T	G C A
N							F 3 5	

N								
N								
N								
N								
N								
N								
N								
N								
N								

N	C							
N	C							
N	C							
N	C							
N	C							
N	C							
N	C							
N	C							
N	C							

N	A	A	A	A	A	A	A	A
N	A	A	A	A	A	A	A	A
N	A	A	A	A	A	A	A	A
N	A	A	A	A	A	A	A	A
N	A	A	A	A	A	A	A	A
N	A	A	A	A	A	A	A	A
N	A	A	A	A	A	A	A	A
N	A	A	A	A	A	A	A	A
N	A	A	A	A	A	A	A	A

Fig. 4 (ii).

Serotype 2











Fig.4(iii).

Serotype 4a



N	N	N	N
C	T	T	T
C	T	T	T
C	T	T	T
C	T	T	T

N	N	N	N
G	G	G	G
G	G	G	G
G	G	G	G
G	G	G	G

N	N	N	N
C	C	C	C
C	C	C	C
C	C	C	C
C	C	C	C

N	N	N	N
A	A	A	A
A	A	A	A
A	A	A	A
A	A	A	A

Fig.4(iv).

Serotype 4b






Fig. 4(v).

ATCC 15313







Fig.4(vi).

ATCC 35152





Fig. 5.



THIS PAGE BLANK (USPTO)




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68	A3	(11) International Publication Number: WO 99/39001 (43) International Publication Date: 5 August 1999 (05.08.99)
(21) International Application Number: PCT/EP99/00918		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 2 February 1999 (02.02.99)		
(30) Priority Data: 98300741.0 2 February 1998 (02.02.98) EP		
(71) Applicant (<i>for all designated States except US</i>): AMERSHAM PHARMACIA BIOTECH AB (SE/SE); Bjorkgatan 30, S-751 84 Uppsala (SE).		
(71)(72) Applicant and Inventor: ULFENDAHL, Per, Johan [SE/SE]; Rapphonsvagen 10B, S-756 53 Uppsala (SE).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(74) Agents: PENNANT, Pyers et al.; 1 Serjeants' Inn, Fleet Street, London EC4Y 1LL (GB).		(88) Date of publication of the international search report: 7 October 1999 (07.10.99)

(54) Title: NUCLEIC ACID ANALYSIS METHOD

(57) Abstract

A nucleic acid analysis method comprises: using a primer to amplify the nucleic acid; providing an array of probes, each probe comprising a sequence identical to the primer and an adjacent sequence; applying fragments of the amplifier nucleic acid under hybridisation conditions to the array; effecting enzymatic chain extension of any probe where the adjacent sequence matches that of a hybridised fragment of the amplified nucleic acid; and observing the location of probes of the array while chain extension has taken place.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 99/00918A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^a	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 630 972 A (HITACHI LTD) 28 December 1994 (1994-12-28) column 12, line 22 - column 6, line 17; figures 6-11 ---	1-16
Y	WO 96 41893 A (UNIV TENNESSEE RES CORP) 27 December 1996 (1996-12-27) page 20, paragraph 3 - page 34, paragraph 1 ---	1-16
Y	WO 97 22720 A (BEATTIE KENNETH LOREN) 26 June 1997 (1997-06-26) figure 1; examples ---	1-16
Y	EP 0 701 001 A (HITACHI LTD) 13 March 1996 (1996-03-13) figure 1; example 1 ---	1-16
		-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 August 1999

Date of mailing of the international search report

24/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Molina Galan, E

1

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/00918

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 93 17126 A (PUBLIC HEALTH RESEARCH INST OF) 2 September 1993 (1993-09-02) figure 4; example 1.1 ---	1-16
A	WO 91 05060 A (APPLIED BIOSYSTEMS) 18 April 1991 (1991-04-18) abstract ---	12,13
A	WO 91 14001 A (DU PONT) 19 September 1991 (1991-09-19) cited in the application ---	
A	EP 0 534 858 A (KEYGENE NV) 31 March 1993 (1993-03-31) ---	
A	EP 0 649 852 A (HITACHI LTD) 26 April 1995 (1995-04-26) -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No

PCT/EP 99/00918

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0630972	A 28-12-1994	JP 7008300	A	13-01-1995
		JP 7039399	A	10-02-1995
		US 5650274	A	22-07-1997
		US 5824481	A	20-10-1998
WO 9641893	A 27-12-1996	AU	6272896	A 09-01-1997
WO 9722720	A 26-06-1997	AU	1687597	A 14-07-1997
EP 0701001	A 13-03-1996	JP 8070898	A	19-03-1996
		CN 1127887	A	31-07-1996
WO 9317126	A 02-09-1993	AU 3728093	A	13-09-1993
		CA 2130562	A	02-09-1993
		EP 0675966	A	11-10-1995
WO 9105060	A 18-04-1991	US 5366860	A	22-11-1994
		AT 131210	T	15-12-1995
		DE 69024061	D	18-01-1996
		DE 69024061	T	08-08-1996
		EP 0496749	A	05-08-1992
		JP 2649102	B	03-09-1997
		JP 5502371	T	28-04-1993
WO 9114001	A 19-09-1991	US 5126239	A	30-06-1992
		AT 115634	T	15-12-1994
		AU 639565	B	29-07-1993
		AU 7782091	A	10-10-1991
		CA 2078132	A	15-09-1991
		DE 69105959	D	26-01-1995
		DE 69105959	T	18-05-1995
		DK 520039	T	20-02-1995
		EP 0520039	A	30-12-1992
		ES 2065684	T	16-02-1995
		FI 924049	A	10-09-1992
		IL 97503	A	26-05-1995
		JP 2818486	B	30-10-1998
		NO 304655	B	25-01-1999
		PL 166895	B	30-06-1995
EP 0534858	A 31-03-1993	AU 672760	B	17-10-1996
		AU 2662992	A	27-04-1993
		CZ 9400669	A	15-12-1994
		WO 9306239	A	01-04-1993
		FI 941360	A	24-05-1994
		HU 68504	A	28-06-1995
		JP 6510668	T	01-12-1994
		NO 941064	A	20-05-1994
		ZA 9207323	A	30-08-1993
EP 0649852	A 26-04-1995	JP 7116000	A	09-05-1995
		CN 1106459	A	09-08-1995
		US 5817464	A	06-10-1998

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)